7 Small-Cap Stocks With Massive Potential Returns

In This Article:

Having a list of small-cap stocks with high growth potential is similar to uncovering hidden gems. These stocks offer significant upside potential for emerging sectors and innovative business models reshaping industries. Here, the focus is on companies and their compelling financial performances and strategic maneuvers. These fundamentals position them as standout investments in 2024. These companies hold solid fundamentals that may support the rapid expansion of their market capital.

Understanding these stocks goes beyond financial metrics; it’s about grasping the disruptive technologies, niche market penetrations, and strategic expansions driving their growth. Whether its pioneering role in genomic diagnostics or dominance in digital gaming, each company showcases unique strengths. These strengths allow these companies to capitalize on evolving consumer trends and market demands.

Those keen on maximizing returns in the small-cap space can greatly benefit from insights into how these companies leverage their strengths to seize opportunities in the health care, industrial and diversified REITs, interactive home entertainment, technology hardware, storage and peripherals, specialized finance, and distribution industries.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

GeneDx (WGS)

a visualization of DNA in a vial. TSHA stock
a visualization of DNA in a vial. TSHA stock

Source: Connect world / Shutterstock.com

GeneDx (NASDAQ:WGS) prevails in genomic diagnostics. In Q1 2024, GeneDx conducted 16,592 tests, marking a remarkable 91% year-over-year (YOY) increase. This surge in testing points to growing demand for their advanced diagnostic services, which include a comprehensive analysis of genetic data to aid clinicians in making precise medical decisions. Financially, GeneDx has demonstrated robust performance with a significant expansion in adjusted gross margins, reaching 61% in Q1 2024 from 34% a year ago.

Moreover, the company reported a 96% YOY growth in revenue from exome and genome tests, totaling $44.0 million for the quarter. These financial gains highlight GeneDx’s effective monetization of proprietary genetic data assets and reflect its ability to capture a larger share of the genomic testing market. Such financial discipline positions GeneDx well on its path toward sustainable profitability.

Overall, GeneDx has high potential on the small-cap stocks list due to its expansion into higher-margin testing and strong revenue growth.

Newlake Capital Partners (NLCP)

Human hand stacking coins over a black background with hexagonal golden shapes. Concept of investment management and portfolio diversification. Composite image between a hand photography and a 3D back, ETFs
Human hand stacking coins over a black background with hexagonal golden shapes. Concept of investment management and portfolio diversification. Composite image between a hand photography and a 3D back, ETFs

Source: Olivier Le Moal / Shutterstock.com

Newlake Capital Partners (OTCMKTS:NLCP) leads in cannabis real estate. The company had a solid increase in adjusted funds from operations (AFFO). The AFFO grew by 10.6% YOY to $11.0 million for Q1 2024. The company increased its quarterly dividend to $0.41 per share. The dividends are equivalent to an annualized rate of $1.64 per share, similar to the increase in Q4 2023. The pattern points to NewLake’s focus on returning value. A high and growing dividend yield is attractive to investors. Hence, these elements indicate financial stability and confidence in future cash flows from the portfolio.